Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension

Yung Hsin Cheng, Kuo Hsuan Hung, Tung Hu Tsai, Chia Jung Lee, Ruy Yu Ku, Allen Wen Hsiang Chiu, Shih Hwa Chiou, Catherine Jui Ling Liu

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Glaucoma is an irreversible ocular disease that may lead to progressive visual field loss and eventually to blindness with inadequately controlled intraocular pressure (IOP). Latanoprost is one of the most potent ocular hypotensive compounds, the current first-line therapy in glaucoma. However, the daily instillation required for efficacy and undesirable side-effects are major causes of treatment adherence failure and persistence in glaucoma therapy. In the present study, we developed an injectable thermosensitive chitosan/gelatin/glycerol phosphate (C/G/GP) hydrogel as a sustained-release system of latanoprost for glaucoma treatment. The latanoprost-loaded C/G/GP hydrogel can gel within 1 min at 37 °C. The results show a sustained release of latanoprost from C/G/GP hydrogel in vitro and in vivo. The latanoprost-loaded C/G/GP hydrogel showed a good in vitro and in vivo biocompatibility. A rabbit model of glaucoma was established by intravitreal injection of triamcinolone acetonide. After a single subconjunctival injection of latanoprost-loaded C/G/GP hydrogel, IOP was significantly decreased within 8 days and then remained at a normal level. The results of the study suggest that latanoprost-loaded C/G/GP hydrogel may have a potential application in glaucoma therapy.

Original languageEnglish
Pages (from-to)4360-4366
Number of pages7
JournalActa Biomaterialia
Volume10
Issue number10
DOIs
Publication statusPublished - Oct 1 2014
Externally publishedYes

Fingerprint

latanoprost
Ocular Hypertension
Hydrogel
Chitosan
Gelatin
Glycerol
Hydrogels
Glaucoma
Phosphates
Intraocular Pressure
Triamcinolone Acetonide
Intravitreal Injections
Injections
Eye Diseases
Biocompatibility
Blindness
Therapeutics
Visual Fields
Treatment Failure
Gels

Keywords

  • Drug delivery
  • Glaucoma
  • Hydrogel
  • Latanoprost

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Medicine(all)

Cite this

Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension. / Cheng, Yung Hsin; Hung, Kuo Hsuan; Tsai, Tung Hu; Lee, Chia Jung; Ku, Ruy Yu; Chiu, Allen Wen Hsiang; Chiou, Shih Hwa; Liu, Catherine Jui Ling.

In: Acta Biomaterialia, Vol. 10, No. 10, 01.10.2014, p. 4360-4366.

Research output: Contribution to journalArticle

Cheng, Yung Hsin ; Hung, Kuo Hsuan ; Tsai, Tung Hu ; Lee, Chia Jung ; Ku, Ruy Yu ; Chiu, Allen Wen Hsiang ; Chiou, Shih Hwa ; Liu, Catherine Jui Ling. / Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension. In: Acta Biomaterialia. 2014 ; Vol. 10, No. 10. pp. 4360-4366.
@article{ad7c2e080540430789ffd7a82962fd5e,
title = "Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension",
abstract = "Glaucoma is an irreversible ocular disease that may lead to progressive visual field loss and eventually to blindness with inadequately controlled intraocular pressure (IOP). Latanoprost is one of the most potent ocular hypotensive compounds, the current first-line therapy in glaucoma. However, the daily instillation required for efficacy and undesirable side-effects are major causes of treatment adherence failure and persistence in glaucoma therapy. In the present study, we developed an injectable thermosensitive chitosan/gelatin/glycerol phosphate (C/G/GP) hydrogel as a sustained-release system of latanoprost for glaucoma treatment. The latanoprost-loaded C/G/GP hydrogel can gel within 1 min at 37 °C. The results show a sustained release of latanoprost from C/G/GP hydrogel in vitro and in vivo. The latanoprost-loaded C/G/GP hydrogel showed a good in vitro and in vivo biocompatibility. A rabbit model of glaucoma was established by intravitreal injection of triamcinolone acetonide. After a single subconjunctival injection of latanoprost-loaded C/G/GP hydrogel, IOP was significantly decreased within 8 days and then remained at a normal level. The results of the study suggest that latanoprost-loaded C/G/GP hydrogel may have a potential application in glaucoma therapy.",
keywords = "Drug delivery, Glaucoma, Hydrogel, Latanoprost",
author = "Cheng, {Yung Hsin} and Hung, {Kuo Hsuan} and Tsai, {Tung Hu} and Lee, {Chia Jung} and Ku, {Ruy Yu} and Chiu, {Allen Wen Hsiang} and Chiou, {Shih Hwa} and Liu, {Catherine Jui Ling}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.actbio.2014.05.031",
language = "English",
volume = "10",
pages = "4360--4366",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier BV",
number = "10",

}

TY - JOUR

T1 - Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension

AU - Cheng, Yung Hsin

AU - Hung, Kuo Hsuan

AU - Tsai, Tung Hu

AU - Lee, Chia Jung

AU - Ku, Ruy Yu

AU - Chiu, Allen Wen Hsiang

AU - Chiou, Shih Hwa

AU - Liu, Catherine Jui Ling

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Glaucoma is an irreversible ocular disease that may lead to progressive visual field loss and eventually to blindness with inadequately controlled intraocular pressure (IOP). Latanoprost is one of the most potent ocular hypotensive compounds, the current first-line therapy in glaucoma. However, the daily instillation required for efficacy and undesirable side-effects are major causes of treatment adherence failure and persistence in glaucoma therapy. In the present study, we developed an injectable thermosensitive chitosan/gelatin/glycerol phosphate (C/G/GP) hydrogel as a sustained-release system of latanoprost for glaucoma treatment. The latanoprost-loaded C/G/GP hydrogel can gel within 1 min at 37 °C. The results show a sustained release of latanoprost from C/G/GP hydrogel in vitro and in vivo. The latanoprost-loaded C/G/GP hydrogel showed a good in vitro and in vivo biocompatibility. A rabbit model of glaucoma was established by intravitreal injection of triamcinolone acetonide. After a single subconjunctival injection of latanoprost-loaded C/G/GP hydrogel, IOP was significantly decreased within 8 days and then remained at a normal level. The results of the study suggest that latanoprost-loaded C/G/GP hydrogel may have a potential application in glaucoma therapy.

AB - Glaucoma is an irreversible ocular disease that may lead to progressive visual field loss and eventually to blindness with inadequately controlled intraocular pressure (IOP). Latanoprost is one of the most potent ocular hypotensive compounds, the current first-line therapy in glaucoma. However, the daily instillation required for efficacy and undesirable side-effects are major causes of treatment adherence failure and persistence in glaucoma therapy. In the present study, we developed an injectable thermosensitive chitosan/gelatin/glycerol phosphate (C/G/GP) hydrogel as a sustained-release system of latanoprost for glaucoma treatment. The latanoprost-loaded C/G/GP hydrogel can gel within 1 min at 37 °C. The results show a sustained release of latanoprost from C/G/GP hydrogel in vitro and in vivo. The latanoprost-loaded C/G/GP hydrogel showed a good in vitro and in vivo biocompatibility. A rabbit model of glaucoma was established by intravitreal injection of triamcinolone acetonide. After a single subconjunctival injection of latanoprost-loaded C/G/GP hydrogel, IOP was significantly decreased within 8 days and then remained at a normal level. The results of the study suggest that latanoprost-loaded C/G/GP hydrogel may have a potential application in glaucoma therapy.

KW - Drug delivery

KW - Glaucoma

KW - Hydrogel

KW - Latanoprost

UR - http://www.scopus.com/inward/record.url?scp=84908229587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908229587&partnerID=8YFLogxK

U2 - 10.1016/j.actbio.2014.05.031

DO - 10.1016/j.actbio.2014.05.031

M3 - Article

C2 - 24914827

AN - SCOPUS:84908229587

VL - 10

SP - 4360

EP - 4366

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

IS - 10

ER -